Investigating radiotherapy response in a novel syngeneic model of prostate cancer
AuthorsHaughey, C. M.
Steele, R. E.
Mullan, P. B.
Buckley, N. E.
S, S. M.
Illidge, Timothy M
Mills, I. G.
Eddie, S. L.
AffiliationPatrick G Johnston Centre for Cancer Research, Queen's University, Belfast
MetadataShow full item record
AbstractThe prostate cancer (PCa) field lacks clinically relevant, syngeneic mouse models which retain the tumour microenvironment observed in PCa patients. This study establishes a cell line from prostate tumour tissue derived from the Pten-/-/trp53-/- mouse, termed DVL3 which when subcutaneously implanted in immunocompetent C57BL/6 mice, forms tumours with distinct glandular morphology, strong cytokeratin 8 and androgen receptor expression, recapitulating high-risk localised human PCa. Compared to the commonly used TRAMP C1 model, generated with SV40 large T-antigen, DVL3 tumours are immunologically cold, with a lower proportion of CD8+ T-cells, and high proportion of immunosuppressive myeloid derived suppressor cells (MDSCs), thus resembling high-risk PCa. Furthermore, DVL3 tumours are responsive to fractionated RT, a standard treatment for localised and metastatic PCa, compared to the TRAMP C1 model. RNA-sequencing of irradiated DVL3 tumours identified upregulation of type-1 interferon and STING pathways, as well as transcripts associated with MDSCs. Upregulation of STING expression in tumour epithelium and the recruitment of MDSCs following irradiation was confirmed by immunohistochemistry. The DVL3 syngeneic model represents substantial progress in preclinical PCa modelling, displaying pathological, micro-environmental and treatment responses observed in molecular high-risk disease. Our study supports using this model for development and validation of treatments targeting PCa, especially novel immune therapeutic agents.
CitationHaughey CM, Mukherjee D, Steele RE, Popple A, Dura-Perez L, Pickard A, et al. Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers (Basel). 2020;12(10).
- A comparative study of peptide-based imaging agents [<sup>68</sup>Ga]Ga-PSMA-11, [<sup>68</sup>Ga]Ga-AMBA, [<sup>68</sup>Ga]Ga-NODAGA-RGD and [<sup>68</sup>Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models.
- Authors: Zhang-Yin J, Provost C, Cancel-Tassin G, Rusu T, Penent M, Radulescu C, Comperat E, Cussenot O, Montravers F, Renard-Penna R, Talbot JN, Prignon A
- Issue date: 2020 May - Jun
- PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
- Authors: Vidotto T, Saggioro FP, Jamaspishvili T, Chesca DL, Picanço de Albuquerque CG, Reis RB, Graham CH, Berman DM, Siemens DR, Squire JA, Koti M
- Issue date: 2019 Jun
- Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
- Authors: Philippou Y, Sjoberg HT, Murphy E, Alyacoubi S, Jones KI, Gordon-Weeks AN, Phyu S, Parkes EE, Gillies McKenna W, Lamb AD, Gileadi U, Cerundolo V, Scheiblin DA, Lockett SJ, Wink DA, Mills IG, Hamdy FC, Muschel RJ, Bryant RJ
- Issue date: 2020 Sep
- Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
- Authors: Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM
- Issue date: 1997 Aug 15
- Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.
- Authors: Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP
- Issue date: 2018 May